Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.
Xiao K, Zhang Z, Wu Y, Li G, Chen J, Ren Y, Yang N, Zhou J, Zhang W, Wang J, Zhong Z, Xia S, Wang G, Li N, Li W, Feng L, Zhang W, Su W, Dai G.
Xiao K, et al. Among authors: wu y.
ACS Med Chem Lett. 2025 Feb 13;16(3):454-463. doi: 10.1021/acsmedchemlett.4c00625. eCollection 2025 Mar 13.
ACS Med Chem Lett. 2025.
PMID: 40104804